NASDAQ:CODXCo-Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Co-Diagnostics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.97 +1.03 (+5.74 %) (As of 07/8/2020 04:00 PM ET) Add Compare Share Today's Range$17.91Now: $18.97▼$19.2050-Day Range$15.32MA: $17.52▼$19.4652-Week Range$0.81Now: $18.97▼$29.72Volume2.10 million shsAverage Volume2.99 million shsMarket Capitalization$520.92 millionP/E RatioN/ADividend YieldN/ABeta-2.56 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingCo-Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Co-Diagnostics has a potential downside of 10.4% from its current price of $18.97.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesCo-Diagnostics has received 242 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCo-Diagnostics has received 268 “underperform” votes. (Add your “underperform” vote.)Community SentimentCo-Diagnostics has received 52.55% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote “Outperform” if you believe CODX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,367,000.00 in company stock.Percentage Held by InsidersOnly 9.00% of the stock of Co-Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 7.91% of the stock of Co-Diagnostics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Co-Diagnostics are expected to decrease by -34.90% in the coming year, from $1.92 to $1.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -57.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -57.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 189.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.78 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CODX Previous Symbol CUSIPN/A CIK1692415 Webwww.codiagnostics.com Phone801-438-1036Debt Debt-to-Equity RatioN/A Current Ratio16.44 Quick Ratio15.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio9.88 P/E GrowthN/A Sales & Book Value Annual Sales$220,000.00 Price / Sales2,367.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book189.70Profitability EPS (Most Recent Fiscal Year)($0.36) Net Income$-6,200,000.00 Net Margins-334.58% Return on Equity-81.15% Return on Assets-74.06%Miscellaneous Employees22 Outstanding Shares27,460,000Market Cap$520.92 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:CODX Rates by TradingView Receive CODX News and Ratings via Email Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter. Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions How has Co-Diagnostics' stock been impacted by COVID-19 (Coronavirus)? Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CODX shares have increased by 43.8% and is now trading at $18.97. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Co-Diagnostics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Co-Diagnostics. When is Co-Diagnostics' next earnings date? Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Co-Diagnostics. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics Inc (NASDAQ:CODX) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. The firm had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.10 million. Co-Diagnostics had a negative net margin of 334.58% and a negative return on equity of 81.15%. View Co-Diagnostics' earnings history. What price target have analysts set for CODX? 2 Wall Street analysts have issued 1 year price objectives for Co-Diagnostics' stock. Their forecasts range from $4.00 to $30.00. On average, they anticipate Co-Diagnostics' share price to reach $17.00 in the next year. This suggests that the stock has a possible downside of 10.4%. View analysts' price targets for Co-Diagnostics. Has Co-Diagnostics been receiving favorable news coverage? Media coverage about CODX stock has trended negative on Thursday, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Co-Diagnostics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Co-Diagnostics. Who are some of Co-Diagnostics' key competitors? Some companies that are related to Co-Diagnostics include Cantel Medical (CMD), AtriCure (ATRC), Glaukos (GKOS), Shockwave Medical (SWAV), Luminex (LMNX), Axonics Modulation Technologies (AXNX), Silk Road Medical (SILK), Atrion (ATRI), Cerus (CERS), Cardiovascular Systems (CSII), GenMark Diagnostics (GNMK), Vapotherm (VAPO), OraSure Technologies (OSUR), Tactile Systems Technology (TCMD) and Orthopediatrics (KIDS). View all competitors. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Moderna (MRNA), Advanced Micro Devices (AMD), Vaxart (VXRT), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU) and Alibaba Group (BABA). Who are Co-Diagnostics' key executives? Co-Diagnostics' management team includes the following people: Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 66)Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 42)Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 71)Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic AlliancesMr. Cameron Gundry, Head of Commercialization LATAM/EUR When did Co-Diagnostics IPO? (CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO. What is Co-Diagnostics' stock symbol? Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX." How do I buy shares of Co-Diagnostics? Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Co-Diagnostics' stock price today? One share of CODX stock can currently be purchased for approximately $18.97. How big of a company is Co-Diagnostics? Co-Diagnostics has a market capitalization of $520.92 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 22 workers across the globe. What is Co-Diagnostics' official website? The official website for Co-Diagnostics is www.codiagnostics.com. How can I contact Co-Diagnostics? Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected] This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
